Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Spinal Muscular Atrophy Market, by Type
1.4.2 North America Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 North America Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 North America Spinal Muscular Atrophy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market
Chapter 4. North America Spinal Muscular Atrophy Treatment Market by Type
4.1 North America Type 1 Market by Country
4.2 North America Type 2 Market by Country
4.3 North America Type 3 Market by Country
4.4 North America Type 4 Market by Country
Chapter 5. North America Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 North America Injection Market by Country
5.2 North America Oral Market by Country
Chapter 6. North America Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 North America Drug Market by Country
6.2 North America Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 North America Spinraza Market by Country
6.2.2 North America Zolgensma (AVXS-101) Market by Country
6.2.3 North America Evrysdi Market by Country
6.2.4 North America Others Market by Country
6.3 North America Gene Therapy Market by Country
Chapter 7. North America Spinal Muscular Atrophy Treatment Market by Country
7.1 US Spinal Muscular Atrophy Treatment Market
7.1.1 US Spinal Muscular Atrophy Treatment Market by Type
7.1.2 US Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.3 US Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 US Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 Canada Spinal Muscular Atrophy Treatment Market
7.2.1 Canada Spinal Muscular Atrophy Treatment Market by Type
7.2.2 Canada Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.3 Canada Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 Canada Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 Mexico Spinal Muscular Atrophy Treatment Market
7.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Type
7.3.2 Mexico Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.3 Mexico Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 Mexico Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 Rest of North America Spinal Muscular Atrophy Treatment Market
7.4.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Type
7.4.2 Rest of North America Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.3 Rest of North America Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 Rest of North America Spinal Muscular Atrophy Treatment Market by Drug Type
Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:
Unique Offerings 
